Systemic treatment for metastatic or recurrent disease

Sameh Mikhai, Tanios Bekaii-Saab

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The majority of patients with esophageal cancer develop metastasis during the course of their disease [1]. Chemotherapy, therefore, remains the mainstay of treatment of patients with advanced esophageal cancer and is predominantly used to prolong survival and preserve quality of life [1]. According to data from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program, the 5-year survival for patients with esophageal cancer improved only modestly over the last 50 years, from 4 % in the years 1950-1954 to 12-17 % during the period 1994-2002 and 20 % in 2006 [2]. Despite a large number of clinical trials, there is no consensus as to the best regimen for initial treatment of patients with advanced gastroesophageal cancer. In the majority of cases, chemotherapy for advanced esophageal and esophagogastric junction (GEJ) adenocarcinoma, squamous cell carcinoma of the esophagus, and gastric adenocarcinoma is often used interchangeably [3]. The comparison of chemotherapy versus best supportive care consistently demonstrated signifi cant benefit in overall survival (OS) favoring chemotherapy (hazard ratio [HR] 0.36; 95 % confidence interval [CI] 0.24-0.55), which translates into a benefi t of approximately 6 months [1, 4]. Similarly, the comparison of combination versus single-agent chemotherapy provided evidence for improved OS infavor of combination chemotherapy (HR 0.82; 95 % CI 0.74-0.90) [1]. It remains a matter of debate, however, if combinations of three cytotoxic agents offer any advantage over two-drug combinations [1, 5].

Original languageEnglish (US)
Title of host publicationEsophageal Cancer
Subtitle of host publicationPrevention, Diagnosis and Therapy
PublisherSpringer International Publishing
Pages221-244
Number of pages24
ISBN (Electronic)9783319200682
ISBN (Print)9783319200675
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Drug Therapy
Esophageal Neoplasms
Survival
SEER Program
Confidence Intervals
Therapeutics
Esophagogastric Junction
National Cancer Institute (U.S.)
Cytotoxins
Drug Combinations
Combination Drug Therapy
Squamous Cell Carcinoma
Stomach
Adenocarcinoma
Quality of Life
Clinical Trials
Neoplasm Metastasis
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Mikhai, S., & Bekaii-Saab, T. (2015). Systemic treatment for metastatic or recurrent disease. In Esophageal Cancer: Prevention, Diagnosis and Therapy (pp. 221-244). Springer International Publishing. https://doi.org/10.1007/978-3-319-20068-2_14

Systemic treatment for metastatic or recurrent disease. / Mikhai, Sameh; Bekaii-Saab, Tanios.

Esophageal Cancer: Prevention, Diagnosis and Therapy. Springer International Publishing, 2015. p. 221-244.

Research output: Chapter in Book/Report/Conference proceedingChapter

Mikhai, S & Bekaii-Saab, T 2015, Systemic treatment for metastatic or recurrent disease. in Esophageal Cancer: Prevention, Diagnosis and Therapy. Springer International Publishing, pp. 221-244. https://doi.org/10.1007/978-3-319-20068-2_14
Mikhai S, Bekaii-Saab T. Systemic treatment for metastatic or recurrent disease. In Esophageal Cancer: Prevention, Diagnosis and Therapy. Springer International Publishing. 2015. p. 221-244 https://doi.org/10.1007/978-3-319-20068-2_14
Mikhai, Sameh ; Bekaii-Saab, Tanios. / Systemic treatment for metastatic or recurrent disease. Esophageal Cancer: Prevention, Diagnosis and Therapy. Springer International Publishing, 2015. pp. 221-244
@inbook{2adde1e671584b5c8eb648eb7387bb51,
title = "Systemic treatment for metastatic or recurrent disease",
abstract = "The majority of patients with esophageal cancer develop metastasis during the course of their disease [1]. Chemotherapy, therefore, remains the mainstay of treatment of patients with advanced esophageal cancer and is predominantly used to prolong survival and preserve quality of life [1]. According to data from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program, the 5-year survival for patients with esophageal cancer improved only modestly over the last 50 years, from 4 {\%} in the years 1950-1954 to 12-17 {\%} during the period 1994-2002 and 20 {\%} in 2006 [2]. Despite a large number of clinical trials, there is no consensus as to the best regimen for initial treatment of patients with advanced gastroesophageal cancer. In the majority of cases, chemotherapy for advanced esophageal and esophagogastric junction (GEJ) adenocarcinoma, squamous cell carcinoma of the esophagus, and gastric adenocarcinoma is often used interchangeably [3]. The comparison of chemotherapy versus best supportive care consistently demonstrated signifi cant benefit in overall survival (OS) favoring chemotherapy (hazard ratio [HR] 0.36; 95 {\%} confidence interval [CI] 0.24-0.55), which translates into a benefi t of approximately 6 months [1, 4]. Similarly, the comparison of combination versus single-agent chemotherapy provided evidence for improved OS infavor of combination chemotherapy (HR 0.82; 95 {\%} CI 0.74-0.90) [1]. It remains a matter of debate, however, if combinations of three cytotoxic agents offer any advantage over two-drug combinations [1, 5].",
author = "Sameh Mikhai and Tanios Bekaii-Saab",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-3-319-20068-2_14",
language = "English (US)",
isbn = "9783319200675",
pages = "221--244",
booktitle = "Esophageal Cancer",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Systemic treatment for metastatic or recurrent disease

AU - Mikhai, Sameh

AU - Bekaii-Saab, Tanios

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The majority of patients with esophageal cancer develop metastasis during the course of their disease [1]. Chemotherapy, therefore, remains the mainstay of treatment of patients with advanced esophageal cancer and is predominantly used to prolong survival and preserve quality of life [1]. According to data from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program, the 5-year survival for patients with esophageal cancer improved only modestly over the last 50 years, from 4 % in the years 1950-1954 to 12-17 % during the period 1994-2002 and 20 % in 2006 [2]. Despite a large number of clinical trials, there is no consensus as to the best regimen for initial treatment of patients with advanced gastroesophageal cancer. In the majority of cases, chemotherapy for advanced esophageal and esophagogastric junction (GEJ) adenocarcinoma, squamous cell carcinoma of the esophagus, and gastric adenocarcinoma is often used interchangeably [3]. The comparison of chemotherapy versus best supportive care consistently demonstrated signifi cant benefit in overall survival (OS) favoring chemotherapy (hazard ratio [HR] 0.36; 95 % confidence interval [CI] 0.24-0.55), which translates into a benefi t of approximately 6 months [1, 4]. Similarly, the comparison of combination versus single-agent chemotherapy provided evidence for improved OS infavor of combination chemotherapy (HR 0.82; 95 % CI 0.74-0.90) [1]. It remains a matter of debate, however, if combinations of three cytotoxic agents offer any advantage over two-drug combinations [1, 5].

AB - The majority of patients with esophageal cancer develop metastasis during the course of their disease [1]. Chemotherapy, therefore, remains the mainstay of treatment of patients with advanced esophageal cancer and is predominantly used to prolong survival and preserve quality of life [1]. According to data from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program, the 5-year survival for patients with esophageal cancer improved only modestly over the last 50 years, from 4 % in the years 1950-1954 to 12-17 % during the period 1994-2002 and 20 % in 2006 [2]. Despite a large number of clinical trials, there is no consensus as to the best regimen for initial treatment of patients with advanced gastroesophageal cancer. In the majority of cases, chemotherapy for advanced esophageal and esophagogastric junction (GEJ) adenocarcinoma, squamous cell carcinoma of the esophagus, and gastric adenocarcinoma is often used interchangeably [3]. The comparison of chemotherapy versus best supportive care consistently demonstrated signifi cant benefit in overall survival (OS) favoring chemotherapy (hazard ratio [HR] 0.36; 95 % confidence interval [CI] 0.24-0.55), which translates into a benefi t of approximately 6 months [1, 4]. Similarly, the comparison of combination versus single-agent chemotherapy provided evidence for improved OS infavor of combination chemotherapy (HR 0.82; 95 % CI 0.74-0.90) [1]. It remains a matter of debate, however, if combinations of three cytotoxic agents offer any advantage over two-drug combinations [1, 5].

UR - http://www.scopus.com/inward/record.url?scp=84944217876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944217876&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-20068-2_14

DO - 10.1007/978-3-319-20068-2_14

M3 - Chapter

SN - 9783319200675

SP - 221

EP - 244

BT - Esophageal Cancer

PB - Springer International Publishing

ER -